LEADER 04206nam  22005535  450 
001 9910337947103321
005 20200702145532.0
010   $a3-030-16624-4
024 7 $a10.1007/978-3-030-16624-3
035   $a(CKB)4100000008347180
035   $a(MiAaPQ)EBC5785811
035   $a(DE-He213)978-3-030-16624-3
035   $a(PPN)238492893
035   $a(EXLCZ)994100000008347180
100   $a20190604d2019      u|             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aCancer Stem Cell Resistance to Targeted Therapy$b[electronic resource] /$fedited by Cristina Maccalli, Matilde Todaro, Soldano Ferrone
205   $a1st ed. 2019.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019.
215   $a1 online resource (267 pages)
225 1 $aResistance to Targeted Anti-Cancer Therapeutics,$x2196-5501 ;$v19
311   $a3-030-16623-6 
327   $aCancer Stem Cells: from birth to death -- A Cancer Stem Cell Perspective on Minimal Residual Disease in Solid Malignancies -- Cancer Stem Cells in Lung Cancer: Roots of Drug Resistance and Targets for Novel Therapeutic Strategies -- Overexpression of YY1 Regulates the Resistance of Cancer Stem Cells: Targeting YY1 -- Cancer Stem Cell Challenges in Melanoma Characterization and Treatment -- Harnessing the immune system to target cancer cells -- Targeting leukemia stem cells and the immunological bone marrow microenvironment -- Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy -- Cancer stem cells: the players of immune evasion from immunotherapy -- Index.
330   $aThis book represents an updated summary of the state of the art of the characterization of cancer stem cell/cancer initiating cell (CSC/CIC) properties. Experts provide an overview of the definition and biological properties of CSCs/CICs as well as the role of these cells in determining the resistance to standard and immune-based therapies. It also discusses limitations in the achievement of a definitive biological characterization of CSCs/CICs due to their high extent of plasticity and heterogeneity that is also mutually driven by the interaction of these cells with the tumor microenvironment. The limitations in targeting CSCs/CICs with immunotherapy are also explained together with explorative combination approaches that could increase the susceptibility of these cells to the recognition by immune cells. This book is conceived for a broad audience, including students, teachers, scientific experts. The critical revision of available results in terms of immunological profile of CSCs/CICs and the efficacy in targeting these cells by immunological approaches, results in a comprehensive and up to date recapitulation of the field and provides interesting suggestions on how to focus future investigations in order to assess the role of CSCs/CICs as prognostic and predictive biomarkers of responsiveness to therapies for cancer patients.
410  0$aResistance to Targeted Anti-Cancer Therapeutics,$x2196-5501 ;$v19
606   $aCancer research
606   $aImmunology
606   $aMolecular biology
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
606   $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000
606   $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X
615  0$aCancer research.
615  0$aImmunology.
615  0$aMolecular biology.
615 14$aCancer Research.
615 24$aImmunology.
615 24$aMolecular Medicine.
676   $a616.994061
702   $aMaccalli$b Cristina$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aTodaro$b Matilde$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aFerrone$b Soldano$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910337947103321
996   $aCancer Stem Cell Resistance to Targeted Therapy$91945690
997   $aUNINA